Avotermin
Also known as: Avotermin, Juvista, recombinant human TGF-beta3, rhTGF-β3, TGF‑β3
Source Avotermin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Avotermin (recombinant human TGF‑beta3) is an investigational growth‑factor therapy intended to improve the cosmetic appearance of surgical scars. In clinical studies it is given as a single intradermal injection to wound edges at the time of closure, with the aim of promoting scar‑free healing and producing smoother, less visible scars.
Mechanism of Action
Avotermin supplies exogenous TGF‑beta3, an isoform that predominates in fetal wound healing where scar formation is minimal. TGF‑beta3 modulates fibroblast activity, extracellular‑matrix deposition, and collagen organization, shifting the balance away from the profibrotic TGF‑beta1/2 pathways. By enhancing regenerative signaling, it encourages more orderly tissue repair and reduces hypertrophic scar formation.
What the Research Shows
Pre‑clinical work identified TGF‑beta3 as a key mediator of scar‑free healing. Early phase I/II trials reported that intradermal avotermin administered at wound closure produced short‑term and ≥12‑month improvements in scar appearance versus placebo. A randomized, double‑blind phase II study (156 patients) showed a statistically significant benefit for the highest dose (500 ng/100 µL per cm) on lay‑panel scar scores. Reviews note the unmet need for scar prophylaxis and highlight avotermin as the first agent with robust trial data, while also emphasizing that larger, later‑phase studies are still lacking.
Reported Benefits
Clinical evidence demonstrates that a single intradermal dose of avotermin can significantly improve the visual quality of surgical scars, particularly at higher concentrations. Benefits include smoother texture, reduced redness, and better overall cosmetic outcome, which may lessen the psychological impact of scarring for patients. The therapy is well tolerated in the studied populations.
Limitations of the Evidence
Evidence is confined to phase I/II trials with modest sample sizes; no phase III data or regulatory approval exist. Only the highest dose showed clear efficacy, leaving optimal dosing uncertain. Long‑term safety beyond the trial periods is not fully characterized, and the topical formulation lacks clinical validation. Potential effects on tumor biology remain theoretical, though low acute doses appear unlikely to promote cancer.
Safety Considerations
Trials reported avotermin to be well tolerated, with no serious adverse events attributed to the drug. As a growth factor, theoretical concerns about stimulating unwanted cell proliferation have been raised, but current data suggest that brief, low‑dose exposure does not markedly influence tumor initiation or progression. Ongoing monitoring for unexpected effects is advisable.
How It Is Administered
Avotermin is administered as an intradermal injection directly into the wound margins at the time of surgical closure, typically in a volume of 100 µL per linear centimeter of wound edge. Topical formulations are mentioned in the literature, but clinical data supporting their use are not available.
Routes of Administration
Goals & Uses
- Scar preventionDermatology / Wound HealingModerate
- improved wound healingTherapeuticLow
- Reduction of hypertrophic scarringDermatologyLow
- scar reductionCosmeticModerate
- Improved cosmetic wound outcomesAesthetic MedicineLow
Contraindications
- Active infection at wound siteInfectionModerate
- History of keloid or abnormal scarring disordersDermatologyModerate
- Known hypersensitivity to TGF-β3 or excipientsAllergyHigh
- hypersensitivity to TGF‑β3AllergyHigh
Adverse Effects
- Injection site painLocalCommonPain at the injection site
- PruritusDermatologicCommonItching
- Contact dermatitisDermatologicalUncommon
- Injection site edemaLocal ReactionCommon
- Hypersensitivity reactionImmunologicRare
- erythemaLocalCommon
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- NSAIDsLowMay increase renal risk in susceptible patients
- CorticosteroidsModerate
- other topical wound healing agentsLow
Population Constraints
- Patients with active malignancyOncologyRelative
- Pediatric patientsAgeRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trial application submitted; no marketing authorization.
- United StatesInvestigationalInvestigational New Drug (IND) status; not approved.
- United KingdomInvestigationalUnder clinical investigation; not approved.
Not approved by FDA, EMA, or MHRA; classified as an investigational new drug.
Evidence & Sources
- Journal ArticleModerateLaverty HG, et al.2009-01-01T00:00:00.000000Z
- Journal ArticleModeratePotter K, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleModerateOccleston NL, et al.2008-01-01T00:00:00.000000Z
- Journal ArticleModerateDurani P, et al.2008-01-01T00:00:00.000000Z
- Journal ArticleModerateOccleston NL, et al.2009-01-01T00:00:00.000000Z
- Journal ArticleModerateMcCollum PT, et al.2011-01-01T00:00:00.000000Z
Frequently Asked Questions
How is avotermin given to patients?
In the studied trials avotermin is injected intradermally along the wound edges immediately after the skin is closed, using a small volume per centimeter of incision.
What scar improvements have been observed?
Patients receiving the highest tested dose showed statistically significant reductions in scar thickness, redness, and overall visual scores compared with placebo, with benefits persisting for at least a year.
Is avotermin approved for clinical use?
No. Avotermin remains an investigational product; it has not received regulatory approval for any indication.
Are there safety concerns related to cancer risk?
Reviews suggest that acute, low‑dose exposure to TGF‑beta3 is unlikely to promote tumor growth, and trial data have not identified cancer‑related adverse events, but definitive conclusions await longer‑term studies.
Can avotermin be used topically instead of injection?
Topical use is mentioned in the literature, but no clinical trials have evaluated its efficacy or safety; current evidence supports only the intradermal injection approach.
What is Avotermin?
Avotermin (recombinant human TGF‑beta3) is an investigational growth‑factor therapy intended to improve the cosmetic appearance of surgical scars. In clinical studies it is given as a single intradermal injection to wound edges at the time of closure, with the aim of promoting scar‑free healing and producing smoother, less visible scars.
What is Avotermin used for?
Avotermin is educationally associated with: Scar prevention, improved wound healing, Reduction of hypertrophic scarring, scar reduction, Improved cosmetic wound outcomes. Educational only — not medical advice.
How is Avotermin administered?
Recorded routes of administration: Intradermal, Topical.
What are the potential side effects of Avotermin?
Reported adverse effects include: Injection site pain, Pruritus, Contact dermatitis, Injection site edema, Hypersensitivity reaction, erythema, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Avotermin?
Recorded contraindications: Active infection at wound site, History of keloid or abnormal scarring disorders, Known hypersensitivity to TGF-β3 or excipients, hypersensitivity to TGF‑β3. Consult a qualified clinician before use.